MicroRNA-122 as a diagnostic biomarker for hepatocellular carcinoma related to hepatitis C virus: a meta-analysis and systematic review
Objective MicroRNA-122 (miR-122) has been identified as a biomarker of liver diseases. However, the miR-122 detection accuracy in patients with hepatocellular carcinoma (HCC) associated with hepatitis C virus (HCV) is inconclusive. Methods We conducted a systematic literature search of Web of Scienc...
Saved in:
| Published in | Journal of international medical research Vol. 48; no. 8; p. 300060520941634 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
London, England
SAGE Publications
01.08.2020
Sage Publications Ltd SAGE Publishing |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0300-0605 1473-2300 1473-2300 |
| DOI | 10.1177/0300060520941634 |
Cover
Loading…
| Abstract | Objective
MicroRNA-122 (miR-122) has been identified as a biomarker of liver diseases. However, the miR-122 detection accuracy in patients with hepatocellular carcinoma (HCC) associated with hepatitis C virus (HCV) is inconclusive.
Methods
We conducted a systematic literature search of Web of Science, Cochrane Library, PubMed, and Embase to identify studies related to the diagnostic value of miR-122 in HCV-related HCC. We analyzed the results and validated them using data from the Cancer Genome Atlas (TCGA).
Results
Six articles were included in this meta-analysis, comprising 354 cases and 420 controls. The pooled specificity, sensitivity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and area under the curve were 0.87, 0.83, 5.1, 0.16, 32, and 0.92, respectively. Additional sub-group analyses showed that results for plasma were more sensitive than those for serum. In addition, miR-122 was better at distinguishing between HCV-associated HCC and healthy people or those with HCV than between those with HCV-associated HCC and HCV-related cirrhosis. Small samples (≤100) had better diagnostic odds ratios than larger samples (>100). Analysis of data from TCGA confirmed that miRNA-122 had a high diagnostic value.
Conclusion
This meta-analysis demonstrates that miR-122 may be a useful diagnostic biomarker for HCV-associated HCC. |
|---|---|
| AbstractList | Objective
MicroRNA-122 (miR-122) has been identified as a biomarker of liver diseases. However, the miR-122 detection accuracy in patients with hepatocellular carcinoma (HCC) associated with hepatitis C virus (HCV) is inconclusive.
Methods
We conducted a systematic literature search of Web of Science, Cochrane Library, PubMed, and Embase to identify studies related to the diagnostic value of miR-122 in HCV-related HCC. We analyzed the results and validated them using data from the Cancer Genome Atlas (TCGA).
Results
Six articles were included in this meta-analysis, comprising 354 cases and 420 controls. The pooled specificity, sensitivity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and area under the curve were 0.87, 0.83, 5.1, 0.16, 32, and 0.92, respectively. Additional sub-group analyses showed that results for plasma were more sensitive than those for serum. In addition, miR-122 was better at distinguishing between HCV-associated HCC and healthy people or those with HCV than between those with HCV-associated HCC and HCV-related cirrhosis. Small samples (≤100) had better diagnostic odds ratios than larger samples (>100). Analysis of data from TCGA confirmed that miRNA-122 had a high diagnostic value.
Conclusion
This meta-analysis demonstrates that miR-122 may be a useful diagnostic biomarker for HCV-associated HCC. Objective MicroRNA-122 (miR-122) has been identified as a biomarker of liver diseases. However, the miR-122 detection accuracy in patients with hepatocellular carcinoma (HCC) associated with hepatitis C virus (HCV) is inconclusive. Methods We conducted a systematic literature search of Web of Science, Cochrane Library, PubMed, and Embase to identify studies related to the diagnostic value of miR-122 in HCV-related HCC. We analyzed the results and validated them using data from the Cancer Genome Atlas (TCGA). Results Six articles were included in this meta-analysis, comprising 354 cases and 420 controls. The pooled specificity, sensitivity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and area under the curve were 0.87, 0.83, 5.1, 0.16, 32, and 0.92, respectively. Additional sub-group analyses showed that results for plasma were more sensitive than those for serum. In addition, miR-122 was better at distinguishing between HCV-associated HCC and healthy people or those with HCV than between those with HCV-associated HCC and HCV-related cirrhosis. Small samples (≤100) had better diagnostic odds ratios than larger samples (>100). Analysis of data from TCGA confirmed that miRNA-122 had a high diagnostic value. Conclusion This meta-analysis demonstrates that miR-122 may be a useful diagnostic biomarker for HCV-associated HCC. MicroRNA-122 (miR-122) has been identified as a biomarker of liver diseases. However, the miR-122 detection accuracy in patients with hepatocellular carcinoma (HCC) associated with hepatitis C virus (HCV) is inconclusive.OBJECTIVEMicroRNA-122 (miR-122) has been identified as a biomarker of liver diseases. However, the miR-122 detection accuracy in patients with hepatocellular carcinoma (HCC) associated with hepatitis C virus (HCV) is inconclusive.We conducted a systematic literature search of Web of Science, Cochrane Library, PubMed, and Embase to identify studies related to the diagnostic value of miR-122 in HCV-related HCC. We analyzed the results and validated them using data from the Cancer Genome Atlas (TCGA).METHODSWe conducted a systematic literature search of Web of Science, Cochrane Library, PubMed, and Embase to identify studies related to the diagnostic value of miR-122 in HCV-related HCC. We analyzed the results and validated them using data from the Cancer Genome Atlas (TCGA).Six articles were included in this meta-analysis, comprising 354 cases and 420 controls. The pooled specificity, sensitivity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and area under the curve were 0.87, 0.83, 5.1, 0.16, 32, and 0.92, respectively. Additional sub-group analyses showed that results for plasma were more sensitive than those for serum. In addition, miR-122 was better at distinguishing between HCV-associated HCC and healthy people or those with HCV than between those with HCV-associated HCC and HCV-related cirrhosis. Small samples (≤100) had better diagnostic odds ratios than larger samples (>100). Analysis of data from TCGA confirmed that miRNA-122 had a high diagnostic value.RESULTSSix articles were included in this meta-analysis, comprising 354 cases and 420 controls. The pooled specificity, sensitivity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and area under the curve were 0.87, 0.83, 5.1, 0.16, 32, and 0.92, respectively. Additional sub-group analyses showed that results for plasma were more sensitive than those for serum. In addition, miR-122 was better at distinguishing between HCV-associated HCC and healthy people or those with HCV than between those with HCV-associated HCC and HCV-related cirrhosis. Small samples (≤100) had better diagnostic odds ratios than larger samples (>100). Analysis of data from TCGA confirmed that miRNA-122 had a high diagnostic value.This meta-analysis demonstrates that miR-122 may be a useful diagnostic biomarker for HCV-associated HCC.CONCLUSIONThis meta-analysis demonstrates that miR-122 may be a useful diagnostic biomarker for HCV-associated HCC. MicroRNA-122 (miR-122) has been identified as a biomarker of liver diseases. However, the miR-122 detection accuracy in patients with hepatocellular carcinoma (HCC) associated with hepatitis C virus (HCV) is inconclusive. We conducted a systematic literature search of Web of Science, Cochrane Library, PubMed, and Embase to identify studies related to the diagnostic value of miR-122 in HCV-related HCC. We analyzed the results and validated them using data from the Cancer Genome Atlas (TCGA). Six articles were included in this meta-analysis, comprising 354 cases and 420 controls. The pooled specificity, sensitivity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and area under the curve were 0.87, 0.83, 5.1, 0.16, 32, and 0.92, respectively. Additional sub-group analyses showed that results for plasma were more sensitive than those for serum. In addition, miR-122 was better at distinguishing between HCV-associated HCC and healthy people or those with HCV than between those with HCV-associated HCC and HCV-related cirrhosis. Small samples (≤100) had better diagnostic odds ratios than larger samples (>100). Analysis of data from TCGA confirmed that miRNA-122 had a high diagnostic value. This meta-analysis demonstrates that miR-122 may be a useful diagnostic biomarker for HCV-associated HCC. |
| Author | Ding, Jing Tian, Wen-guang Wei, Xiao-yu Yu, Yi-Chuan |
| Author_xml | – sequence: 1 givenname: Xiao-yu orcidid: 0000-0001-5780-5756 surname: Wei fullname: Wei, Xiao-yu organization: Department of Infectious Diseases, Yongchuan Hospital of Chongqing Medical University, Chongqing, P.R. China – sequence: 2 givenname: Jing surname: Ding fullname: Ding, Jing organization: Department of Infectious Diseases, Yongchuan Hospital of Chongqing Medical University, Chongqing, P.R. China – sequence: 3 givenname: Wen-guang surname: Tian fullname: Tian, Wen-guang organization: Department of Infectious Diseases, Yongchuan Hospital of Chongqing Medical University, Chongqing, P.R. China – sequence: 4 givenname: Yi-Chuan surname: Yu fullname: Yu, Yi-Chuan email: yuyichuany@qq.com organization: Department of Emergency, Yongchuan Hospital of Chongqing Medical University, Chongqing, P.R. China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32790532$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kk1v1DAQhiNURLeFOydkiUsvAX874YBUrfioVEBCcLYmzmTrJRsvdlK0v4C_jdNtga4EvljyPPPOOzM-KY6GMGBRPGX0BWPGvKSCUqqp4rSWTAv5oFgwaUTJ8_tRsZjD5Rw_Lk5SWlMquVb8UXEsuKmpEnxR_PzgXQyfP56XjHMCiQBpPayGkEbvSOPDBuI3jKQLkVzhFsbgsO-nHiJxEJ0fMkAi9jBiS8awZ_zoE1mSax-n9CorbnCEEgbodykHYGhJ2qURNzDXiHjt8cfj4mEHfcInt_dp8fXtmy_L9-Xlp3cXy_PL0ilejSWXitK6bVjjVINYd47VtDHQUK3yYY4pYWqlnAIUpkNsWlFpbButgdW8EafFxV63DbC22-hzfzsbwNubhxBXFmK21aNtbyqh6TqhpdOsYtrVQnKBhsuqM1nr9V5rOzUbbB0OY4T-nuj9yOCv7CpcW6OkYBXNAme3AjF8nzCNduPTPF8YMEzJcimkNExSntHnB-g6TDGPdKakEFVuXGfq2d-Oflu523cG9B7IS08pYmedH_MawmzQ95ZRO38se_ixciI9SLzT_k9KuU9JsMI_dv_J_wIqp9uU |
| CitedBy_id | crossref_primary_10_3390_cimb46110711 crossref_primary_10_3390_pharmaceutics14071380 crossref_primary_10_4251_wjgo_v13_i4_197 crossref_primary_10_1016_j_ncrna_2022_01_004 crossref_primary_10_3390_cancers13071563 crossref_primary_10_3390_bios15010058 crossref_primary_10_4251_wjgo_v13_i5_351 |
| Cites_doi | 10.1172/JCI63455 10.1371/journal.pone.0041561 10.5114/aoms.2019.86621 10.1016/j.clinre.2017.06.004 10.1258/acb.2008.008088 10.7150/jca.24978 10.3892/or.2017.5676 10.1007/s13277-016-5097-8 10.1038/onc.2009.211 10.3390/ijms20040864 10.1177/0394632016648176 10.1038/sj.bjc.6601018 10.1016/j.gendis.2017.10.003 10.1002/mc.20712 10.1371/journal.ppat.1005714 10.1002/jcp.25135 10.3390/ijms18050906 10.3892/mco.2013.119 10.3389/fnmol.2016.00052 10.4251/wjgo.v11.i2.153 10.1128/JVI.02575-07 10.31557/APJCP.2019.20.8.2515 10.1371/journal.ppat.1006374 10.4254/wjh.v6.i11.818 10.3390/ijms20030605 10.1051/medsci/20132910013 10.4149/neo_2013_018 10.1111/j.1440-1746.1997.tb00398.x 10.1111/hepr.12606 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2020 The Author(s) 2020. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2020 2020 SAGE Publications |
| Copyright_xml | – notice: The Author(s) 2020 – notice: The Author(s) 2020. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2020 2020 SAGE Publications |
| DBID | AFRWT AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1177/0300060520941634 |
| DatabaseName | Sage Journals GOLD Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: AFRWT name: Sage Journals Online Open Access url: http://journals.sagepub.com/ sourceTypes: Publisher – sequence: 5 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1473-2300 |
| ExternalDocumentID | oai_doaj_org_article_d009dbe7ff364c61816c93423e7248f7 PMC7543180 32790532 10_1177_0300060520941634 10.1177_0300060520941634 |
| Genre | Meta-Analysis Systematic Review Journal Article |
| GrantInformation_xml | – fundername: he foundation of Program of Technology of Science and Technology Committee of Yuzhong District in Chongqing grantid: Ycst2015nc5029 – fundername: ; grantid: Ycst2015nc5029 |
| GroupedDBID | --- .55 .GJ 01A 0R~ 29K 2WC 44B 53G 54M 5GY 5RE 5VS 7X7 8FI 8FJ AABQO AACKU AAFWJ AAGGD AAJIQ AAJOX AAJPV AAJQC AANSI AAPEO AAQQG AAQXH AASGM AAXOT AAYTG AAZBJ ABAFQ ABAWP ABDWY ABHKI ABJNI ABNCE ABPGX ABQKF ABQXT ABUWG ABVFX ABXGC ABYTW ACARO ACFMA ACFYK ACGBL ACGFS ACLHI ACROE ADBBV ADEIA ADMPF ADOGD ADQSQ ADTBJ ADUKL AECVZ AEFTW AENEX AERKM AEUHG AEWDL AEXFG AFCOW AFKBI AFKRA AFKRG AFPKN AFRWT AIGRN AJABX AJEFB AJMMQ AJSCY AJUZI ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AUTPY AYAKG BAWUL BCNDV BDDNI BENPR BPHCQ BSEHC BVXVI CBRKF CCPQU CORYS CQQTX CUTAK D-I DC. DF. DIK E3Z EBD EBS EF0 EJD EMOBN F5P FYUFA GROUPED_DOAJ GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION H13 HMCUK HYE J8X K.F KQ8 L7B MK0 O9- P2P PHGZM PHGZT PIMPY PQQKQ Q1R ROL RPM S01 SAUOL SCDPB SCNPE SFC SV3 TR2 TUS UKHRP X7M ZE2 ZGI AAYXX ACHEB CITATION OVT AAEJI CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c528t-245009db1bc5bee9fc190b7ab0655551c1537955c5ae37feebd386edb66a192b3 |
| IEDL.DBID | DOA |
| ISSN | 0300-0605 1473-2300 |
| IngestDate | Wed Aug 27 01:12:08 EDT 2025 Thu Aug 21 18:40:27 EDT 2025 Fri Sep 05 12:09:53 EDT 2025 Fri Jul 25 21:19:07 EDT 2025 Mon Jul 21 05:49:28 EDT 2025 Thu Apr 24 23:01:00 EDT 2025 Tue Jul 01 05:27:59 EDT 2025 Tue Jun 17 22:26:38 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | microRNA-122 hepatitis C virus meta-analysis diagnosis plasma hepatocellular carcinoma |
| Language | English |
| License | Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c528t-245009db1bc5bee9fc190b7ab0655551c1537955c5ae37feebd386edb66a192b3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 These authors contributed equally to this work. |
| ORCID | 0000-0001-5780-5756 |
| OpenAccessLink | https://doaj.org/article/d009dbe7ff364c61816c93423e7248f7 |
| PMID | 32790532 |
| PQID | 2443381536 |
| PQPubID | 4451107 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d009dbe7ff364c61816c93423e7248f7 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7543180 proquest_miscellaneous_2434471402 proquest_journals_2443381536 pubmed_primary_32790532 crossref_citationtrail_10_1177_0300060520941634 crossref_primary_10_1177_0300060520941634 sage_journals_10_1177_0300060520941634 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-08-01 |
| PublicationDateYYYYMMDD | 2020-08-01 |
| PublicationDate_xml | – month: 08 year: 2020 text: 2020-08-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | London, England |
| PublicationPlace_xml | – name: London, England – name: England – name: London – name: Sage UK: London, England |
| PublicationTitle | Journal of international medical research |
| PublicationTitleAlternate | J Int Med Res |
| PublicationYear | 2020 |
| Publisher | SAGE Publications Sage Publications Ltd SAGE Publishing |
| Publisher_xml | – name: SAGE Publications – name: Sage Publications Ltd – name: SAGE Publishing |
| References | Mizuguchi, Takizawa, Yoshida 2016; 46 Weis, Marquart, Calvopina 2019; 20 Xu, Wu, Che 2011; 50 Ono, Fukuhara, Motooka 2017; 13 Ali, Abdel Hameed, Effat 2017; 41 Zekri, Youssef, El-Desouky 2016; 37 Huang, Liu, Ma 2016; 231 Gao, Xu, Wang 2018; 18 Liu, Long, Miao 2017; 38 Tsai, Hsu, Hsu 2012; 122 El-Garem, Ammer, Shehab 2014; 6 Coulouarn, Factor, Andersen 2009; 28 Sun, Su, Liu 2018; 9 Gougelet, Colnot 2013; 29 Kuwana, Ichida, Kamimura 1997; 12 Chang, Guo, Jiang 2008; 82 El-Ahwany, Mourad, Zoheiry 2019; 15 Qi, Wang, Katayama 2013; 60 Kanda, Yasui, Nakamura 2017; 18 Choi, Hwang, Kim 2016; 9 Amr, Elmawgoud Atia, Elazeem Elbnhawy 2017; 4 Zhao, Ju, Li 2013; 1 Duan, Wang, Xu 2019; 11 Cui, He, Zhang 2003; 88 Imai, Takai, Hanai 2019; 20 Chen, Zhang, Wang 2016; 29 Wang, Yuan, Cho 2012; 7 Gu, Chen, Zhao 2009; 46 Kim, Lee, Cho 2016; 12 Shehab-Eldeen, Nada, Abou-Elela 2019; 20 bibr19-0300060520941634 bibr14-0300060520941634 bibr30-0300060520941634 bibr22-0300060520941634 bibr15-0300060520941634 bibr6-0300060520941634 bibr28-0300060520941634 Kanda T (bibr7-0300060520941634) 2017; 18 bibr13-0300060520941634 bibr2-0300060520941634 bibr21-0300060520941634 bibr29-0300060520941634 bibr16-0300060520941634 bibr12-0300060520941634 bibr25-0300060520941634 bibr3-0300060520941634 bibr8-0300060520941634 bibr20-0300060520941634 bibr17-0300060520941634 bibr4-0300060520941634 bibr24-0300060520941634 Gao S (bibr9-0300060520941634) 2018; 18 bibr11-0300060520941634 bibr26-0300060520941634 bibr18-0300060520941634 bibr23-0300060520941634 bibr1-0300060520941634 bibr27-0300060520941634 bibr10-0300060520941634 bibr5-0300060520941634 |
| References_xml | – volume: 60 start-page: 135 year: 2013 end-page: 142 article-title: Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. publication-title: Neoplasma – volume: 9 start-page: 52 year: 2016 article-title: Transgenic mouse expressing optical microRNA reporter for monitoring microRNA-124 action during development publication-title: Front Mol Neurosci – volume: 38 start-page: 53 year: 2017 end-page: 62 article-title: Fisetin inhibits liver cancer growth in a mouse model: relation to dopamine receptor. publication-title: Oncol Rep – volume: 29 start-page: 475 year: 2016 end-page: 479 article-title: Safety of implanting sustained-release 5-fluorouracil into hepatic cross-section and omentum majus after primary liver cancer resection publication-title: Int J Immunopathol Pharmacol – volume: 18 start-page: 3305 year: 2018 end-page: 3313 article-title: Diagnostic utility of plasma lncRNA small nucleolar RNA host gene 1 in patients with hepatocellular carcinoma. publication-title: Mol Med Rep – volume: 29 start-page: 861 year: 2013 end-page: 867 article-title: [microRNA: new diagnostic and therapeutic tools in liver disease?]. publication-title: Med Sci (Paris) – volume: 9 start-page: 2631 year: 2018 end-page: 2639 article-title: Serum and exosome long non coding RNAs as potential biomarkers for hepatocellular carcinoma publication-title: J Cancer – volume: 231 start-page: 328 year: 2016 end-page: 335 article-title: Systematic review and meta-analysis: circulating miRNAs for diagnosis of hepatocellular carcinoma. publication-title: J Cell Physiol – volume: 18 start-page: 906 year: 2017 article-title: Real-world experiences with the combination treatment of ledipasvir plus sofosbuvir for 12 weeks in HCV genotype 1-infected Japanese patients: achievement of a sustained virological response in previous users of peginterferon plus ribavirin with HCV NS3/4Ai publication-title: Int J Mol Sci – volume: 122 start-page: 2884 year: 2012 end-page: 2897 article-title: MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. publication-title: J Clin Invest – volume: 46 start-page: 391 year: 2016 end-page: 406 article-title: Dysregulated miRNA in progression of hepatocellular carcinoma: a systematic review. publication-title: Hepatol Res – volume: 50 start-page: 136 year: 2011 end-page: 142 article-title: Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. publication-title: Mol Carcinog – volume: 12 start-page: 149 year: 1997 end-page: 155 article-title: Risk factors and the effect of interferon therapy in the development of hepatocellular carcinoma: a multivariate analysis in 343 patients publication-title: J Gastroenterol Hepatol – volume: 6 start-page: 818 year: 2014 end-page: 824 article-title: Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. publication-title: World J Hepatol – volume: 37 start-page: 12273 year: 2016 end-page: 12286 article-title: Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection. publication-title: Tumour Biol – volume: 12 start-page: e1005714 year: 2016 article-title: Hepatitis C virus core protein promotes miR-122 destabilization by inhibiting GLD-2. publication-title: PLoS Pathog – volume: 41 start-page: e51 year: 2017 end-page: e62 article-title: Circulating microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma publication-title: Clin Res Hepatol Gastroenterol – volume: 1 start-page: 593 year: 2013 end-page: 598 article-title: Tumor markers for hepatocellular carcinoma. publication-title: Mol Clin Oncol – volume: 7 start-page: e41561 year: 2012 article-title: Comparing the microRNA spectrum between serum and plasma. publication-title: PLoS One – volume: 4 start-page: 215 year: 2017 end-page: 221 article-title: Early diagnostic evaluation of miR-122 and miR-224 as biomarkers for hepatocellular carcinoma publication-title: Genes Dis – volume: 11 start-page: 153 year: 2019 end-page: 160 article-title: Feasibility of terahertz imaging for discrimination of human hepatocellular carcinoma. publication-title: World J Gastrointest Oncol – volume: 13 start-page: e1006374 year: 2017 article-title: Characterization of miR-122-independent propagation of HCV. publication-title: PLoS Pathog – volume: 28 start-page: 3526 year: 2009 end-page: 3536 article-title: Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. publication-title: Oncogene – volume: 20 start-page: 864 year: 2019 article-title: Serum microRNAs as biomarkers in hepatitis C: preliminary evidence of a microRNA panel for the diagnosis of hepatocellular carcinoma publication-title: Int J Mol Sci – volume: 20 start-page: 605 year: 2019 article-title: Homeostatic Model Assessment of insulin resistance for predicting the recurrence of hepatocellular carcinoma after curative treatment publication-title: Int J Mol Sci – volume: 15 start-page: 1454 year: 2019 end-page: 1461 article-title: MicroRNA-122a as a non-invasive biomarker for HCV genotype 4-related hepatocellular carcinoma in Egyptian patients. publication-title: Arch Med Sci – volume: 20 start-page: 2515 year: 2019 end-page: 2522 article-title: Diagnostic performance of microRNA-122 and microRNA-224 in hepatitis C virus-induced hepatocellular carcinoma (HCC) publication-title: Asian Pac J Cancer Prev – volume: 82 start-page: 8215 year: 2008 end-page: 8223 article-title: Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. publication-title: J Virol – volume: 88 start-page: 1878 year: 2003 end-page: 1882 article-title: Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein. publication-title: Br J Cancer – volume: 46 start-page: 38 year: 2009 end-page: 43 article-title: Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases publication-title: Ann Clin Biochem – ident: bibr24-0300060520941634 doi: 10.1172/JCI63455 – ident: bibr28-0300060520941634 doi: 10.1371/journal.pone.0041561 – ident: bibr20-0300060520941634 doi: 10.5114/aoms.2019.86621 – ident: bibr15-0300060520941634 doi: 10.1016/j.clinre.2017.06.004 – ident: bibr29-0300060520941634 doi: 10.1258/acb.2008.008088 – ident: bibr8-0300060520941634 doi: 10.7150/jca.24978 – ident: bibr1-0300060520941634 doi: 10.3892/or.2017.5676 – ident: bibr19-0300060520941634 doi: 10.1007/s13277-016-5097-8 – ident: bibr14-0300060520941634 doi: 10.1038/onc.2009.211 – ident: bibr27-0300060520941634 doi: 10.3390/ijms20040864 – ident: bibr2-0300060520941634 doi: 10.1177/0394632016648176 – ident: bibr30-0300060520941634 doi: 10.1038/sj.bjc.6601018 – ident: bibr16-0300060520941634 doi: 10.1016/j.gendis.2017.10.003 – ident: bibr26-0300060520941634 doi: 10.1002/mc.20712 – ident: bibr13-0300060520941634 doi: 10.1371/journal.ppat.1005714 – ident: bibr10-0300060520941634 doi: 10.1002/jcp.25135 – volume: 18 start-page: 906 year: 2017 ident: bibr7-0300060520941634 publication-title: Int J Mol Sci doi: 10.3390/ijms18050906 – ident: bibr22-0300060520941634 doi: 10.3892/mco.2013.119 – ident: bibr12-0300060520941634 doi: 10.3389/fnmol.2016.00052 – ident: bibr5-0300060520941634 doi: 10.4251/wjgo.v11.i2.153 – volume: 18 start-page: 3305 year: 2018 ident: bibr9-0300060520941634 publication-title: Mol Med Rep – ident: bibr25-0300060520941634 doi: 10.1128/JVI.02575-07 – ident: bibr18-0300060520941634 doi: 10.31557/APJCP.2019.20.8.2515 – ident: bibr6-0300060520941634 doi: 10.1371/journal.ppat.1006374 – ident: bibr17-0300060520941634 doi: 10.4254/wjh.v6.i11.818 – ident: bibr3-0300060520941634 doi: 10.3390/ijms20030605 – ident: bibr23-0300060520941634 doi: 10.1051/medsci/20132910013 – ident: bibr11-0300060520941634 doi: 10.4149/neo_2013_018 – ident: bibr21-0300060520941634 doi: 10.1111/j.1440-1746.1997.tb00398.x – ident: bibr4-0300060520941634 doi: 10.1111/hepr.12606 |
| SSID | ssj0042652 |
| Score | 2.2986615 |
| SecondaryResourceType | review_article |
| Snippet | Objective
MicroRNA-122 (miR-122) has been identified as a biomarker of liver diseases. However, the miR-122 detection accuracy in patients with hepatocellular... MicroRNA-122 (miR-122) has been identified as a biomarker of liver diseases. However, the miR-122 detection accuracy in patients with hepatocellular carcinoma... Objective MicroRNA-122 (miR-122) has been identified as a biomarker of liver diseases. However, the miR-122 detection accuracy in patients with hepatocellular... |
| SourceID | doaj pubmedcentral proquest pubmed crossref sage |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 300060520941634 |
| SubjectTerms | Biomarkers Biomarkers, Tumor - genetics Carcinoma, Hepatocellular - diagnosis Hepacivirus - genetics Hepatitis Hepatitis C Hepatitis C - complications Hepatitis C - diagnosis Humans Liver cancer Liver cirrhosis Liver Neoplasms - diagnosis Liver Neoplasms - genetics Meta-Analysis MicroRNAs MicroRNAs - genetics |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEBbt5tJL6btu06JCWSjE7NrWw-qlJCEhFLIsIYHcjF5uAq2drr2F_IL-7c7Y8rrbR_bggzRetDsz0idp5htC3ifCKiGdinOtZMwkE7HKuYJH6UrJpSodJgqfLsTJBft8yS_DgVsTwiqHObGbqF1t8Yx8BssQ7KbAP8Wnm-8xVo3C29VQQuM-2YEpOOcTsnNwtFieDXMxLD883CNgeZU5Hy8qZ9iGTSlscACUsK2FqePv_xfo_Dt28rcAsG5NOn5EHgYwSfd77T8m93z1hEyXPRv17R49H5Ormj06pcuRp_r2Kfl5isF4Z4v9OElTqhuqqesD70CeYl4-hu6sKMBaegWrVlvjKT-GrVKLFYgqEKBdLox3tK17GaRIoof0x_Vq3XyEb_zmWx3rwHxCdeXoyB1N-7yZZ-Ti-Oj88CQOdRliy9O8jVPGAZk5kxjLjfeqtIAqjNQG4Ax8Egtakopzy7XPZOm9cVkuvDNCaACUJntOJlVd-ZeEMu0yJoRyc82YTZ2RpWLcGuZhtyw0j8hsUEphA2k51s74WiQDT_kfaozIh80bNz1hxx2yB6jnjRxSbXcN9epLETy3cN1v9bIsM8GsAEQE5o28iV6mLC9lRHYHKymC_zfFaK0RebfpBs9FRenK12uUQbZF2OCmEXnRG9VmJFmKxGkZ9Mgtc9sa6nZPdX3VsYNLZDfI5xGZomGOQ_rfn_Dq7vG_Jg9SPGLoYh53yaRdrf0bwGGteRuc7Rfl2i0z priority: 102 providerName: ProQuest – databaseName: Sage Journals GOLD Open Access dbid: AFRWT link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9NAEF6V9sIFlbehoEVCkZBqEq_3YXNBoSKqkFpVVSp6s_blthKxq8RGyi_gbzPjR0woIHLIwTtJNt6Z3c8733xLyNtI2lQql4aJTlXIFZdhmogU3nKXK6HS3GGh8MmpPL7gXy7F5Q4p-lqY7g6u3iOtCnrUTNYY3bgbPe6SjGPwTBQSQQoHAgr-sa4WWbvb3R-qgVcwPV0vMLNtkQ-5DvvqtntkjynJIQr2prPzr_N-7oblSnR5BzyOZSKGxOad39xayBq9_z-B1Ltcy18IY80aNtsnDzrwSaettzwkO754REZnrXr1-pDOh2Ks1SEd0bNB13r9mPw4QfLe-ek0jBijekU1dS1RD-wp1vEj1WdJAQbTa1jlqhKzAkhzpRZPLCrAgDa1M97RqmxtUFKJHtHvN8t69QG-ceErHepOKYXqwtFBa5q2dTZPyMXs8_zoOOzOcQitYEkVMi4AyTkTGSuM92luAYUYpQ3AH3hFFmZdlQphhfaxyr03Lk6kd0ZKDQDUxE_JblEW_jmhXLuYS5m6iebcMmdUnnJhDffwdC21CMi4H5TMdiLneNbGtyzqdc1_G8aAvNt84rYV-PiH7Scc540dSnM3F8rlVdZFeuaa_-pVnseSWwkICsIBdRa9YjzJVUAOei_Jem_PAGTFgJ1ELAPyZtMMkY4DpQtf1miD6ozwQMwC8qx1qk1PYoZCazG0qC132-rqdktxc92oiStUQ0gmARmhYw5d-ttNePG_hi_JfYabEw1b8oDsVsvavwIEV5nXXdj9BDTCPug priority: 102 providerName: SAGE Publications |
| Title | MicroRNA-122 as a diagnostic biomarker for hepatocellular carcinoma related to hepatitis C virus: a meta-analysis and systematic review |
| URI | https://journals.sagepub.com/doi/full/10.1177/0300060520941634 https://www.ncbi.nlm.nih.gov/pubmed/32790532 https://www.proquest.com/docview/2443381536 https://www.proquest.com/docview/2434471402 https://pubmed.ncbi.nlm.nih.gov/PMC7543180 https://doaj.org/article/d009dbe7ff364c61816c93423e7248f7 |
| Volume | 48 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9tAEF7a9NJL6btqU7OFYihE2FrtQ9ubE2xCIcYYh_om9iUSSOViy4X8gv7tzkiyFfd5qQ8yaEdi2ZnVfCt98y0h7xPptFRex5nRKuaKy1hnQsOh8IUSShceC4UvpvL8kn9aiuWdrb6QE9bIAzcDN_AAArwNqihSyZ2EhAR3R9m6oBjPirqOHHLebjHVPIMh7QjWfZQcQCSj8AhSPhCA8IMkVGv1_w5g_sqTvEP2qvPP5DF51AJHOmo6_ITcC-VT0p81ytO3J3TRFVJtTmifzjpN6ttn5PsFEu_m01GcMEbNhhrqG5Id2FOswUeazpoChKVXkKGqFb7RR4oqdbjbUAkGtK57CZ5Wq8YG5ZDoGf12vd5uPsIdv4TKxKZVOaGm9LTTiaZNjcxzcjkZL87O43YPhtgJllUx46J2QGKdsCHowgGCsMpYgC7wSxw8MZUWwgkTUlWEYH2ayeCtlAbAo01fkKNyVYZXhHLjUy6l9kPDuWPeqkJz4SwPsDKWRkRksHNK7lqBctwn4yZPdprkP7kxIh_2V3xtxDn-YnuKft7boax2fQKCLW-DLf9XsEXkeBcleTvXNzkAJFjnwzjIiLzbN8MsRUeZMqy2aIPKirCYZRF52QTVvicpQ5G0FFrUQbgddPWwpby-qpXAFSoZZMOI9DEwuy79aRBe_49BeEMeMnzpULMgj8lRtd6Gt4DMKtsj99VS9ciD0WT-eQH_p-PpbN6rpyYcx5PhD8g4NwQ |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbG9gAviDuBAUaCSkiL2jq-JEgIbWNTx9aqmjppb5ljO2wSJKNNQf0F_Bt-I-fk0lAue1sf8mCfpm7OPT7-DiGv-tJEUtnID3WkfK649KNQRHBJbaqEilKLB4WHIzk44R9Pxeka-dmchcGyysYmloba5gbfkXfBDUE2Bfop319-9bFrFO6uNi00KrE4dIvvkLLN3h18AP6-Zmx_b7I78OuuAr4RLCx8xgXEFTbpJ0YkzkWpAZ-YKJ2AM4ZP38BvqEgII7QLVOpcYoNQOptIqSEcSgK47w2yAWFGBFq0sbM3Gh83th_cnaj3LbCdS0-0G6NdHMMhBgkVBEF8xRGW_QL-FeT-Xav5W8FZ6QP375DbdfBKtytpu0vWXHaPdMYV-vVii07aw1yzLdqh4xYXe3Gf_Bhi8d_xaNvvM0b1jGpqq0I_oKeIA4ClQlMKYTQ9By9Z5LirgGWy1GDHowwIaHn2xlla5BUNQjLRXfrtYjqfvYU7fnGF9nWNtEJ1ZmmLVU2rczoPyMm1cOwhWc_yzD0mlGsbcCkj29OcG2YTlUZcmIQ7yM6lFh7pNkyJTQ2Sjr06Psf9Bhf9DzZ65M3yG5cVQMgVtDvI5yUdQnuXA_n0U1xbitiW_9WpNA0kNxIiMFAnxGl0ivEwVR7ZbKQkru3NLG61wyMvl9NgKZBROnP5HGkQ3RESauaRR5VQLVcSMARqC2BGrYjbylJXZ7KL8xKNXCGaQtjzSAcFs13S_x7Ck6vX_4LcHEyGR_HRwejwKbnF8PVGWW-5SdaL6dw9gxiwSJ7XikfJ2XXr-i9gOWqi |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLZgkxAviPuyDTASqoS00CbxJeGtDKpxWVVNndhb5FvYJEimNkXaL-Bvc07iNJQBog95qE8ix-fY_hx_5zMhLyJhMiFtFqYqkyGTTIRZyjO4FLaQXGaFxUTh46k4OmUfzviZ5-ZgLoxvweUrpFVBjZrBGnv3pS2Gfo9xCIGJOiLI4EA8wW6SbcZkAkG9PZ6cfJ53QzHMPtxvI-DpKiPe71Nee8bGvNTI9_8Jc16nTv7C_2qmpMldcsdjSTpunX-P3HDlfTKYtWLUVwd03udWLQ_ogM56meqrB-THMXLxTqbjMIpjqpZUUdvy7sCeYlo-MncWFFAtPYdJq67wIz-yVqnBA4hKMKBNKoyztK5aG1RIoof0-8VitXwNT_zmahUqL3xCVWlpLx1N27SZh-R08m5-eBT6YxlCw-O0DmPGAZhZHWnDtXNZYQBUaKk0oBn4RQYGUZlxbrhyiSyc0zZJhbNaCAV4UiePyFZZlW6HUKZswoTI7EgxZmKrZZExbjRzsFgWigdk2DklN16zHI_O-JpHnUz5b24MyMv1HZetXsc_bN-gn9d2qLTd_FEtvuS-4-a2eVcniyIRzAgARBDdKJvoZMzSQgZkv4uSvAveHDATLP2hHURAnq-LoeOio1TpqhXaoNgirG_jgDxug2pdkyRG3bQESuRGuG1UdbOkvDhvxMElihuko4AMMDD7Kv2tEXb_1_AZuTV7O8k_vZ9-3CO3Y_zs0PAg98lWvVi5J4DNav3U98CfUdotYQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MicroRNA-122+as+a+diagnostic+biomarker+for+hepatocellular+carcinoma+related+to+hepatitis+C+virus%3A+a+meta-analysis+and+systematic+review&rft.jtitle=Journal+of+international+medical+research&rft.au=Wei%2C+Xiao-yu&rft.au=Ding%2C+Jing&rft.au=Tian%2C+Wen-guang&rft.au=Yu%2C+Yi-Chuan&rft.date=2020-08-01&rft.issn=0300-0605&rft.eissn=1473-2300&rft.volume=48&rft.issue=8&rft_id=info:doi/10.1177%2F0300060520941634&rft.externalDBID=n%2Fa&rft.externalDocID=10_1177_0300060520941634 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-0605&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-0605&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-0605&client=summon |